Itraconazole pharmacokinetics in patients with renal dysfunction.
The single-dose pharmacokinetics of 200 mg of oral itraconazole were studied in seven uremic patients, seven patients treated by hemodialysis, and five patients treated by continuous ambulatory peritoneal dialysis. Plasma concentration-versus-time profiles showed wide intersubject variation. This study could not demonstrate any significant effect of renal dysfunction and hemodialysis or continuous ambulatory peritoneal dialysis treatment upon the pharmacokinetics of itraconazole, and firm conclusions concerning dosing in such patients should await confirmation of our data in a larger patient population.
Boelaert
J
J
Renal Unit, Algemeen Ziekenhuis St. Jan, Brugge, Belgium.
Schurgers
M
M
Matthys
E
E
Daneels
R
R
van Peer
A
A
De Beule
K
K
Woestenborghs
R
R
Heykants
J
J
D000284:Administration, Oral; D000368:Aged; D000935:Antifungal Agents / Q000097:blood / Q000493:pharmacokinetics*; D005260:Female; D006801:Humans; D017964:Itraconazole; D007654:Ketoconazole / Q000031:analogs & derivatives* / Q000097:blood / Q000493:pharmacokinetics; D008297:Male; D008875:Middle Aged; D010531:Peritoneal Dialysis, Continuous Ambulatory; D006435:Renal Dialysis; D014511:Uremia / Q000097:blood* / Q000628:therapy
D000935:Antifungal Agents; D017964:Itraconazole; D007654:Ketoconazole